Psychotropic medication non-adherence and associated factors among adult patients with major psychiatric disorders: A protocol for a systematic review

Systematic Reviews

Volumn 7, Issue 1, 2018, Pages

  Semahegn, Agumasie ^a,b   Torpey, Kwasi ^a   Manu, Abubakar ^a   Assefa, Nega ^b   Tesfaye, Gezahegn ^b   Ankomah, Augustine ^a  

^a UNIVERSITY OF GHANA   (Ghana)

^b HARAMAYA UNIVERSITY   (Ethiopia)

Author keywords

Medication non adherence; Meta analysis; Psychiatric disorders; Systematic review

Indexed keywords

PSYCHOTROPIC AGENT;

ARTICLE; BIPOLAR DISORDER; DATA BASE; DATA EXTRACTION; DATA SYNTHESIS; FOLLOW UP; GLOBAL HEALTH; HUMAN; MAJOR DEPRESSION; MEDICATION COMPLIANCE; MENTAL DISEASE; META ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY CONTROL; QUALITY OF LIFE; SCHIZOPHRENIA; SCREENING; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADULT; PSYCHOLOGY;

ADULT; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; GLOBAL HEALTH; HUMANS; MEDICATION ADHERENCE; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA;

EID: 85040861951     PISSN: None     EISSN: 20464053     Source Type: Journal    
DOI: 10.1186/s13643-018-0676-y     Document Type: Article

References (33)

1. World Health Organization. WHO. Mental disorders fact sheet. Reviewed April 2016 [internet]. Geneva 27, Switzerland 2016. Available from: http://www.who.int/mediacentre/factsheets/fs396/en/. Accessed on 16th March, 2017.
2. WHO. The bare facts of medication non-adherence. Geneva: World Health Orgnaization; 2008.
3. Mibel F, Heikki E, Mari L. Non-compliance to medication in Psychiatric patients. Tuku University of Applied Sciences. 2013.
4. Mental Health Foundation. Fundamental facts about mental health. London: Mental health Foundation; 2016.
5. Mathers CDLD. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.
6. WORLD BANK GROUP, World Health Organization. Oout of the shadows: making mental health a global development priority organized by World Bank Group/World Health Organization, April 13-14, 2016 2016. Washington D.C. [internet]. 2016. Available from: http://www.worldbank.org/en/events/2016/03/09/out-of-the-shadows-making-mental-health-a-global-priority
7. WHO. Comprehensive mental health action plan 2013-2020. Genava: World Health organization; 2013. http://www.who.int/mental_health/action_plan_2013/en/.
8. Appleby L, Asherson P, Aznar C, Bebbington P, Bridges S, Brugha T, et al. Mental health and wellbeing in England: adult psychiatric morbidity survey 2014. Leeds; 2016.
9. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;49(2):196-201.
10. Farooq S, Naeem F. Tackling nonadherence in psychiatric disorders: current opinion. Review. Dovepress. Neuropsychiatr Dis Treat. 2014;10:1069-77.
11. Colom F. And VE. Non-adherence in psychiatric disorders: misbehaviour or clinical feature? Acta Psychiatr Scand. 2002;105:161-3.
12. World Health Organization. Adherence to long term therapies: evidence for action. Geneva 27, Switzerland 2003. http://www.who.int/chp/knowledge/publications/adherence:report/en/.
13. Rekha R, Masroor J, Sushma K, et al. Reasons for drug non-compliance of psychiatric patients. J Indian Acad. Appl Psychol. 2005;31(1):24-8.
14. Taj F, Tanwir M, Aly Z, Khowajah AA, Tariq A, Syed FK, et al. Factors associated with non-adherence among psychiatric patients at a tertiary care hospital, Karachi, Pakistan: a questionnaire based cross-sectional study. J Pak Med Assoc. 2008;58(432):432-6.
15. Smith F, Clifford S. Adherence to medication among chronic patients in middle eastern countries: review of studies. East Mediterr Heal J. 2011;17(4):356-63.
16. Lindstrom EBK. Patient compliance with drug therapy in schizophrenia: economic and clinical issues. PharmacoEconomics. 2000;18(2):106-24.
17. Dunn LB, Leckband S, Dolder CR, Pharm D, Leckband SG, Ph R, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia. J Clin Psychiatry. 2002;63(10).
18. Burton WN, Chen C-Y, Conti DJ, Schultz AB, Edington DW. The association of antidepressant medication adherence with employee disability absences. Am J Manag Care. 2007;13(2):105-13.
19. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev [Internet]. 2015;4(1):1-9. Available from: http://www.systematicreviewsjournal.com/content/4/1/1
20. RUTGERS the state University of New Jersey. George F. Smith Library of the Health Sciences. EndNoteX8.0.1(BId 10444), cite while you write TM patented technology U.S patent number 8,092,241. University of Ghana: 3091850168. [internet]. Available from: http://www.libraries.rutgers.edu/sites/default/files/smith/pdf/EndNoteBasic.pdf
21. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa (ON: Ottawa Health Research Institute; 2010.
22. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive meta analysis (CMA) version 2.0. 2004.
23. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;1558:1539-1558.
24. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
25. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(September):629-34.
26. Shi X, Nie C, Shi S, Wang T, Yang H, Zhou Y. Effect comparison between Egger's test and Begg's test in publication bias diagnosis in meta-analyses: evidence from a pilot survey. Int J Res Stud Biosci. 2017;5(5):14-20.
27. Der Simonian R, Laird N. Meta-analysis in clinical trials revisited: HHS public access. Contemp Clin Trials. 2015;45(0 0):139-45.
28. Barkhof E, Meijer CJ, De Sonneville LMJ, Linszen DH, De Haan L. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia-a review of the past decade. Eur Psychiatry [Internet]. 2012;27:9-18. Available from: https://doi.org/10.1016/j.eurpsy.2011.02.005
29. Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol Orig. 2013;3(4):200-18.
30. Aikens JE, Nease DE, Nau DP, Klinkman MS, Schwenk TL. Adherence to maintenance-phase antidepressant medication as a function. Ann Fam Med. 2005;3(1):23-30.
31. Sajatovic M, Davies M, Hrouda DR. Enhancement of treatment adherence among patients with bipolar disorder. Psychiatr Serv 55. 2004;55(3):264-9.
32. Chapman SCE, Horne R. Medication nonadherence and psychiatry: review. Curr Opin Psychiatry. 2013;26(5):446-52.
33. Prakash S. Masand, Miquel Roca, Martin S. Turner JMK. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry. 2009;11(4):148-55.